Short- and long-term changes in gene expression mediated by the activation of TLR9

Molecular Immunology

Volumn 47, Issue 6, 2010, Pages 1317-1324

  Klaschik, Sven ^a   Tross, Debra ^a   Shirota, Hidekazu ^a   Klinman, Dennis M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Gene regulation; Molecular biology; Rodent; Signal transduction

Indexed keywords

B LYMPHOCYTE RECEPTOR; CPG OLIGODEOXYNUCLEOTIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; TOLL LIKE RECEPTOR 9;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL CYCLE; CONTROLLED STUDY; DNA REPAIR; DNA REPLICATION; FEMALE; GENE ACTIVATION; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; IMMUNOGENETICS; IN VIVO STUDY; INNATE IMMUNITY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; UPREGULATION;

ANIMALS; CELL COUNT; CELL CYCLE; DNA DAMAGE; FEMALE; GENE EXPRESSION REGULATION; INJECTIONS, INTRAPERITONEAL; MICE; MICE, INBRED BALB C; NF-KAPPA B; OLIGODEOXYRIBONUCLEOTIDES; RECEPTORS, ANTIGEN, B-CELL; SIGNAL TRANSDUCTION; SPLEEN; TIME FACTORS; TOLL-LIKE RECEPTOR 9;

RODENTIA;

EID: 76949088399     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2009.11.014     Document Type: Article

References (53)

1. Aderem A., and Ulevitch R.J. Toll-like receptors in the induction of the innate immune response. Nature 406 (2000) 782-787
2. Akira S., Takeda K., and Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat. Immunol. 2 (2001) 675-680
3. Ashkar A.A., Bauer S., Mitchell W.J., Vieira J., and Rosenthal K.L. Local delivery of CpG oligodeoxynucleotides induces rapid changes in the genital mucosa and inhibits replication, but not entry, of herpes simplex virus type 2. J. Virol. 77 (2003) 8948-8956
4. Ballas Z.D., Rasmussen W.L., and Krieg A.M. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J. Immunol. 157 (1996) 1840-1847
5. Bauer S., Kirschning C.J., Hacker H., Redecke V., Hausmann S., Akira S., Wagner H., and Lipford G.B. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 9237-9242
6. Bertin S., Anjuere F., Gavelli A., Baque P., Soilihi B.K., Brossette N., Loubat A., and Pierrefite-Carle V. Plasmidic CpG sequences induce tumor microenvironment modifications in a rat liver metastasis model. Int. J. Mol. Med. 21 (2008) 309-315
7. Broide D., Schwarze J., Tighe H., Gifford T., Nguyen M.D., Malek S., Van Uden J., Martin E., Gelfand E.W., and Raz E. Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice. J. Immunol. 161 (1998) 7054-7062
8. Calvano S.E., Xiao W., Richards D.R., Felciano R.M., Baker H.V., Cho R.J., Chen R.O., Brownstein B.H., Cobb J.P., Tschoeke S.K., Miller-Graziano C., Moldawer L.L., Mindrinos M.N., Davis R.W., Tompkins R.G., and Lowry S.F. A network-based analysis of systemic inflammation in humans. Nature 437 (2005) 1032-1037
9. Carpentier A.F., Auf G., and Delattre J.Y. CpG-oligonucleotides for cancer immunotherapy: review of the literature and potential applications in malignant glioma. Front. Biosci. 8 (2003) e115-e127
10. Dong L., Mori I., Hossain M.J., Liu B., and Kimura Y. An immunostimulatory oligodeoxynucleotide containing a cytidine-guanosine motif protects senescence-accelerated mice from lethal influenza virus by augmenting the T helper type 1 response. J. Gen. Virol. 84 (2003) 1623-1628
11. Elkins K.L., Rhinehart-Jones T.R., Stibitz S., Conover J.S., and Klinman D.M. Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria. J. Immunol. 162 (1999) 2291-2298
12. Gao J.J., Diesl V., Wittmann T., Morrison D.C., Ryan J.L., Vogel S.N., and Follettie M.T. Regulation of gene expression in mouse macrophages stimulated with bacterial CpG-DNA and lipopolysaccharide. J. Leukoc. Biol. 72 (2002) 1234-1245
13. Hacker H., Vabulas R.M., Takeuchi O., Hoshino K., Akira S., and Wagner H. Immune cell activation by bacterial CpG-DNA through myeloid differentiation marker 88 and tumor necrosis factor receptor-associated factor (TRAF)6. J. Exp. Med. 192 (2000) 595-600
14. Haining W.N., Davies J., Kanzler H., Drury L., Brenn T., Evans J., Angelosanto J., Rivoli S., Russell K., George S., Sims P., Neuberg D., Li X., Kutok J., Morgan J., Wen P., Demetri G., Coffman R.L., and Nadler L.M. CpG oligodeoxynucleotides alter lymphocyte and dendritic cell trafficking in humans. Clin. Cancer Res. 14 (2008) 5626-5634
15. Halperin S.A., Van Nest G., Smith B., Abtahi S., Whiley H., and Eiden J.J. A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine 21 (2003) 2461-2467
16. Heckelsmiller K., Rall K., Beck S., Schlamp A., Seiderer J., Jahrsdorfer B., Krug A., Rothenfusser S., Endres S., and Hartmann G. Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model. J. Immunol. 169 (2002) 3892-3899
17. Hegele A., Dalpke A., Heeg K., Barth P., Varga Z., Hofmann R., and Olbert P. Immunostimulatory CpG oligonucleotides reduce tumor burden after intravesical administration in an orthotopic murine bladder cancer model. Tumour Biol. 26 (2005) 274-280
18. Hemmi H., Takeuchi O., Kawai T., Sato S., Sanjo H., Matsumoto M., Hoshino K., Wagner H., Takeda K., and Akira S. A Toll-like receptor recognizes bacterial DNA. Nature 408 (2000) 740-745
19. Horner A.A., and Raz E. Immunostimulatory sequence oligodeoxynucleotide-based vaccination and immunomodulation: two unique but complementary strategies for the treatment of allergic diseases. J. Allergy Clin. Immunol. 110 (2002) 706-712
20. Ito S., Ishii K., Shirot H., and Klinman D.M. CpG oligodeoxynucleotides improve the survival of pregnant and fetal mice following Listeria monocytogenes infection. Infect. Immun. 72 (2004) 3543-3548
21. Jahrsdorfer B., Muhlenhoff L., Blackwell S.E., Wagner M., Poeck H., Hartmann E., Jox R., Giese T., Emmerich B., Endres S., Weiner G.J., and Hartmann G. B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides. Clin. Cancer Res. 11 (2005) 1490-1499
22. Jahrsdorfer B., and Weiner G.J. CpG oligodeoxynucleotides for immune stimulation in cancer immunotherapy. Curr. Opin. Invest. Drugs 4 (2003) 686-690
23. Kato A., Homma T., Batchelor J., Hashimoto N., Imai S., Wakiguchi H., Saito H., and Matsumoto K. Interferon-alpha/beta receptor-mediated selective induction of a gene cluster by CpG oligodeoxynucleotide 2006. BMC Immunol. 4 (2003) 8
24. Klaschik S., Tross D., and Klinman D.M. Inductive and suppressive networks regulate TLR9-dependent gene expression in vivo. J. Leukoc. Biol. 85 (2009) 788-795
25. Klaschik S., Gursel I., and Klinman D.M. CpG-mediated changes in gene expression in murine spleen cells identified by microarray analysis. Mol. Immunol. 44 (2007) 1095-1104
26. Klinman D.M., Sechler J.M.G., Conover J., Gu M., and Rosenberg A.S. Contribution of cells at the site of DNA vaccination to the generation of antigen specific immunity and memory. J. Immunol. 158 (1998) 3635-3639
27. Klinman D.M., Yi A., Beaucage S.L., Conover J., and Krieg A.M. CpG motifs expressed by bacterial DNA rapidly induce lymphocytes to secrete IL-6, IL-12 and IFNg. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 2879-2883
28. Krakauer T. Nuclear factor-kappaB: fine-tuning a central integrator of diverse biologic stimuli. Int. Rev. Immunol. 27 (2008) 286-292
29. Krieg A.M. Development of TLR9 agonists for cancer therapy. J. Clin. Invest. 117 (2007) 1184-1194
30. Krieg A.M., Homan L.L., Yi A.K., and Harty J.T. CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge. J. Immunol. 161 (1998) 2428-2434
31. Krieg A.M., Yi A., Matson S., Waldschmidt T.J., Bishop G.A., Teasdale R., Koretzky G.A., and Klinman D.M. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374 (1995) 546-548
32. Leonard J.P., Link B.K., Emmanouilides C., Gregory S.A., Weisdorf D., Andrey J., Hainsworth J., Sparano J.A., Tsai D.E., Horning S., Krieg A.M., and Weiner G.J. Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma. Clin. Cancer Res. 13 (2007) 6168-6174
33. Li Q., and Verma I.M. NF-kappaB regulation in the immune system. Nat. Rev. Immunol. 2 (2002) 725-734
34. Liew F.Y., Xu D., Brint E.K., and O'Neill L.A. Negative regulation of toll-like receptor-mediated immune responses. Nat. Rev. Immunol. 5 (2005) 446-458
35. Roman M., Martin-Orozco E., Goodman J.S., Nguyen M., Sato Y., Ronaghy A., Kornbluth R.S., Richman D.D., Carson D.A., and Raz E. Immunostimulatory DNA sequences function as T helper-1 promoting adjuvants. Nat. Med. 3 (1997) 849-854
36. Schmitz F., Mages J., Heit A., Lang R., and Wagner H. Transcriptional activation induced in macrophages by Toll-like receptor (TLR) ligands: from expression profiling to a model of TLR signaling. Eur. J. Immunol. 34 (2004) 2863-2873
37. Sparwasser T., Koch E., Vabulas R.M., Heeg K., Lipford G.B., Ellwart J.W., and Wager H. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur. J. Immunol. 28 (1998) 2045-2054
38. Sparwasser T., Miethke T., Lipford G., Erdmann A., Hacker H., Heeg K., and Wagner H. Macrophages sense pathogens via DNA motifs: induction of tumor necrosis factor-a-mediated shock. Eur. J. Immunol. 27 (1997) 1671-1679
39. Sparwasser T., Hultner L., Koch E.S., Luz A., Lipford G.B., and Wagner H. Immunostimulatory CpG-oligonucleotides cause extramedullary murine hemopoiesis. J. Immunol. 162 (1999) 2368-2374
40. Stacey K.J., Sweet M.J., and Hume D.A. Macrophages ingest and are activated by bacterial DNA. J. Immunol. 157 (1996) 2116-2120
41. Sun S., Zhang X., Tough D.F., and Sprent J. Type I interferon-mediated stimulation of T cells by CpG DNA. J. Exp. Med. 188 (1998) 2335-2342
42. Takeshita F., Leifer C.A., Gursel I., Ishii K., Takeshita S., Gursel M., and Klinman D.M. Cutting edge: role of toll-like receptor 9 in CpG DNA-induced activation of human cells. J. Immunol. 167 (2001) 3555-3558
43. Takeshita S., Takeshita F., Haddad D.E., Ishii K.J., and Klinman D.M. CpG oligodeoxynucleotides induce murine macrophages to up-regulate chemokine mRNA expression. Cell. Immunol. 206 (2000) 101-106
44. Tross L., Petrenko L., Klaschik S., and Klinman D.M. Global changes in gene expression and synergistic interactions induced by TLR9 and TLR3. Mol. Immunol. 156 (2009) 528-534
45. Verthelyi D., Gursel M., Kenney R.T., Lifson J.D., Liu S., Mican J., and Klinman D.M. CpG oligodeoxynucleotides protect normal and SIV-infected macaques from Leishmania infection. J. Immunol. 170 (2003) 4717-4723
46. Walker P.S., Scharton-Kersten T., Krieg A.M., Love-Homan L., Rowton E.D., Udey M.C., and Vogel J.C. Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12 and IFNg dependent mechanisms. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 6970-6975
47. Weighardt H., Feterowski C., Veit M., Rump M., Wagner H., and Holzmann B. Increased resistance against acute polymicrobial sepsis in mice challenged with immunostimulatory CpG oligodeoxynucleotides is related to an enhanced innate effector cell response. J. Immunol. 165 (2000) 4537-4543
48. Wright G.W., and Simon R.M. A random variance model for detection of differential gene expression in small microarray experiments. Bioinformatics 19 (2003) 2448-2455
49. Yamamoto M., Sato S., Mori K., Hoshino K., Takeuchi O., Takeda K., and Akira S. Cutting edge: a novel Toll/IL-1 receptor domain-containing adapter that preferentially activates the IFN-beta promoter in the Toll-like receptor signaling. J. Immunol. 169 (2002) 6668-6672
50. Yamamoto S., Yamamoto T., Katoaka T., Kuramoto E., Yano O., and Tokunaga T. Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN and augment IFN-mediated natural killer activity. J. Immunol. 148 (1992) 4072-4076
51. Yang Y.H., Dudoit S., Luu P., Lin D.M., Peng V., Ngai J., and Speed T.P. Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res. 30 (2002) e15
52. Zheng L., Asprodites N., Keene A.H., Rodriguez P., Brown K.D., and Davila E. TLR9 engagement on CD4 T lymphocytes represses gamma-radiation-induced apoptosis through activation of checkpoint kinase response elements. Blood 111 (2008) 2704-2713
53. Zimmermann S., Egeter O., Hausmann S., Lipford G.B., Rocken M., Wagner H., and Heeg K. CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine Leishmaniasis. J. Immunol. 160 (1998) 3627-3630